Figure 5.

Simulated steady-state plasma concentration vs. time profiles of tipifarnib 600 mg twice daily in healthy () and cancer () subjects receiving a solid formulation (A), in cancer subjects receiving solid () and liquid formulations () (B), and the effect of body weight <60 kg (), 60–80 kg (), >80 kg () (C) and bilirubin <7.5 mM (), 7.5–15 mM (), >15 mM () concentrations (D) in cancer subjects receiving a solid formulation. Lines represent 10 (lower), 50 (middle) and 90 (upper) quantiles of simulated plasma concentration